<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621148</url>
  </required_header>
  <id_info>
    <org_study_id>FILObsLLC_RESIST</org_study_id>
    <nct_id>NCT05621148</nct_id>
  </id_info>
  <brief_title>REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy</brief_title>
  <acronym>RESIST</acronym>
  <official_title>REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data evaluating and quantifying real-world outcomes of patients post-ibrutinib&#xD;
      discontinuation, as well as outcomes of patients who have progressed on a Bruton tyrosine&#xD;
      kinases inhibitors (BTKi) and received prior venetoclax are very limited. There are no robust&#xD;
      studies specifically designed to assess outcomes of patients with chronic lymphocytic&#xD;
      leukemia (CLL) receiving third line or subsequent treatments. As such, there is no&#xD;
      established standard of care for these multiple Relapsed/Refractory (RR) patients.&#xD;
      Furthermore, despite new oral agents approved in third-line RR CLL, there are limited&#xD;
      published data on how to best sequence these agents and how to manage patients who fail these&#xD;
      therapies. As the best salvage therapy in patients who fail all available oral these agents&#xD;
      is unknown, this is a population of patients with unmet medical need.&#xD;
&#xD;
      The aim of this study is to determine unmet need and treatment patterns of data from two&#xD;
      types of populations, all previously exposed to ibrutinib (or other BTKi) for the full&#xD;
      patient population and both ibrutinib (or other BTKi and venetoclax) for the narrow patient&#xD;
      population, where these agents failed these subcategories of patient populations, at least in&#xD;
      3rd line therapy (in other words, having at least received two lines of therapy before)&#xD;
&#xD;
        -  Patients with prior treatment with BTKi (full patient population) - Underlying tenet:&#xD;
           these patients have been treated with a BTKi in at least one of two or more prior lines&#xD;
           of therapy and progressed - FULL POPULATION&#xD;
&#xD;
        -  Patients who progressed BTKi and failed VEN (defined as patients who discontinued&#xD;
           venetoclax (VEN) due to disease progression, intolerability, or failure to achieve an&#xD;
           objective response within 3 months of initiating therapy; small patient population) -&#xD;
           Tenet: these patients have been treated with both BTKi and VEN in any one of the prior&#xD;
           two lines of therapy and progressed. - NARROW POPULATION&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2023</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of treatment patterns in patients with CLL</measure>
    <time_frame>from BTKi initiation until progression/failure at Venetoclax treatment, assessed up to 7 years</time_frame>
    <description>Overall response rate (complete, partial, stable) for each treatment received</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>CLL, Relapsed</condition>
  <condition>CLL, Refractory</condition>
  <condition>Bruton Tyrosine Kinase Inhibitor</condition>
  <condition>Small Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Full population</arm_group_label>
    <description>LLC patients with prior treatment with BTKi - Underlying tenet: these patients have been treated with a BTKi in at least one of two or more prior lines of therapy and progressed - FULL POPULATION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narrow population</arm_group_label>
    <description>LLC Patients who progressed BTKi and failed VEN (defined as patients who discontinued VEN due to disease progression, intolerability, or failure to achieve an objective response within 3 months of initiating therapy; small patient population) - Tenet: these patients have been treated with both BTKi and VEN in any one of the prior two lines of therapy and progressed</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients previously exposed to ibrutinib (or other BTKi) : treatment with a BTKi in at&#xD;
        least one of two or more prior lines of therapy and progressed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of CLL or small lymphocytic leukemia (SLL).&#xD;
&#xD;
          -  ≥ 18 years of age the time of initial diagnosis.&#xD;
&#xD;
          -  Venetoclax therapy in at least third line of treatment (LOT) during the period&#xD;
             considered, following at least one LOT with BTKi&#xD;
&#xD;
          -  Patients who received VEN during prior LOTs are eligible.&#xD;
&#xD;
          -  Patient not opposed to data collection (including deceased patients)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exposure to cellular therapy, including CAR T-cells / Allo-Stem Cell Transplantation.&#xD;
&#xD;
          -  Richter's transformation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc YSEBAERT</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie ROUILLE</last_name>
    <phone>0247391896</phone>
    <phone_ext>+33</phone_ext>
    <email>v.rouille@filo-leucemie.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie POINSIGNON-BLANCARD</last_name>
    <phone>0247391896</phone>
    <phone_ext>+33</phone_ext>
    <email>m.poinsignon-blancard@filo-leucemie.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Estaing - Hématologie Clinique Adulte</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain GUIEZE, Dr</last_name>
      <phone>+33 4 73 75 00 65</phone>
      <email>rguieze@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard - Hématologie</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Sophie MICHALLET, Dr</last_name>
      <phone>04 78 78 26 41</phone>
      <email>anne-sophie.michallet@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes - Hématologie Clinique</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thérèse AURRAN, Dr</last_name>
      <phone>04 91 22 38 68</phone>
      <email>aurrant@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle TCHERNONOG, Dr</last_name>
      <email>e-tchernonog@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux Pessac</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Sarah DILHUYDY, MD</last_name>
      <phone>+33557656511</phone>
      <email>marie-sarah.dilhuydy@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle FERRANT, MD</last_name>
      <phone>+33478864521</phone>
      <email>emmanuel.ferrant2@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg - Icans</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc FORNECKER, MD</last_name>
      <email>lm.fornecker@icans.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse - IUCT Oncopole - Service d'Hématologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc YSEBAERT, Pr</last_name>
      <email>ysebaert.loic@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>October 28, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>March 16, 2023</last_update_submitted>
  <last_update_submitted_qc>March 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

